Drug intelligence / Profile preview

FREE-003

Development stage: Unknown
Lead developer: Freedom Biosciences

Overview

FREE-003 is an undisclosed neuropsychiatric drug candidate being developed by Freedom Biosciences (formerly Freedom Ventures). As of 2026, the program is in Phase 2 clinical development. While specific details regarding its molecular target and therapeutic modality have not been publicly released, Freedom Biosciences focuses on developing next-generation ketamine-based combinations and 5-HT2A-targeting therapeutics for the treatment of mental health and substance use disorders. The candidate is part of a broader pipeline of novel neuropsychiatric therapies aimed at addressing unmet needs in conditions such as treatment-resistant depression and major depressive disorder.

Beyond the preview

Go deeper on FREE-003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FREE-003.

Explore the full profile